DaVita Inc. (NYSE:DVA) Shares Purchased by Blue Trust Inc.

Blue Trust Inc. boosted its stake in DaVita Inc. (NYSE:DVA) by 56.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 330 shares of the company’s stock after acquiring an additional 119 shares during the period. Blue Trust Inc.’s holdings in DaVita were worth $54,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of DVA. Wedmont Private Capital grew its stake in shares of DaVita by 4.4% in the 3rd quarter. Wedmont Private Capital now owns 1,776 shares of the company’s stock valued at $280,000 after purchasing an additional 75 shares during the last quarter. First Trust Direct Indexing L.P. raised its position in DaVita by 3.9% during the 1st quarter. First Trust Direct Indexing L.P. now owns 2,590 shares of the company’s stock worth $358,000 after buying an additional 98 shares during the last quarter. Quent Capital LLC lifted its stake in shares of DaVita by 21.0% in the 1st quarter. Quent Capital LLC now owns 581 shares of the company’s stock worth $80,000 after acquiring an additional 101 shares during the period. FinTrust Capital Advisors LLC boosted its holdings in shares of DaVita by 17.6% in the first quarter. FinTrust Capital Advisors LLC now owns 837 shares of the company’s stock valued at $116,000 after acquiring an additional 125 shares in the last quarter. Finally, Mather Group LLC. increased its stake in shares of DaVita by 15.5% during the second quarter. Mather Group LLC. now owns 990 shares of the company’s stock worth $137,000 after acquiring an additional 133 shares during the period. Institutional investors and hedge funds own 90.12% of the company’s stock.

Insider Activity at DaVita

In other DaVita news, insider Kathleen Alyce Waters sold 7,857 shares of the company’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total value of $1,148,771.97. Following the transaction, the insider now owns 83,011 shares of the company’s stock, valued at approximately $12,137,038.31. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other DaVita news, insider Kathleen Alyce Waters sold 7,857 shares of the business’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $146.21, for a total value of $1,148,771.97. Following the transaction, the insider now owns 83,011 shares in the company, valued at $12,137,038.31. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Javier Rodriguez sold 32,176 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $155.93, for a total transaction of $5,017,203.68. Following the transaction, the chief executive officer now directly owns 905,659 shares in the company, valued at approximately $141,219,407.87. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 173,482 shares of company stock valued at $27,387,069 over the last 90 days. 2.00% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms have recently commented on DVA. Bank of America raised their price target on DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a report on Wednesday, August 7th. UBS Group upped their price target on shares of DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. Truist Financial raised their price objective on shares of DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research note on Monday, October 7th. TD Cowen upped their target price on shares of DaVita from $139.00 to $150.00 and gave the stock a “hold” rating in a research report on Wednesday, July 24th. Finally, Barclays lifted their price target on shares of DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a research report on Thursday. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $161.80.

DaVita Trading Down 1.0 %

NYSE:DVA opened at $139.81 on Friday. The company has a market cap of $11.73 billion, a PE ratio of 14.89, a P/E/G ratio of 0.90 and a beta of 0.87. The business’s 50 day moving average is $157.96 and its two-hundred day moving average is $145.97. The company has a quick ratio of 1.12, a current ratio of 1.16 and a debt-to-equity ratio of 9.94. DaVita Inc. has a 52 week low of $76.17 and a 52 week high of $168.50.

DaVita (NYSE:DVA) last released its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). The company had revenue of $3.26 billion for the quarter, compared to analyst estimates of $3.25 billion. DaVita had a net margin of 6.86% and a return on equity of 77.00%. The company’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.85 EPS. On average, analysts predict that DaVita Inc. will post 9.99 EPS for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.